0001493152-22-014555.txt : 20220520 0001493152-22-014555.hdr.sgml : 20220520 20220520110821 ACCESSION NUMBER: 0001493152-22-014555 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220520 DATE AS OF CHANGE: 20220520 EFFECTIVENESS DATE: 20220520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Coya Therapeutics, Inc. CENTRAL INDEX KEY: 0001835022 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-446377 FILM NUMBER: 22946228 BUSINESS ADDRESS: STREET 1: 12645 MEMORIAL DR., SUITE F1 #305 CITY: HOUSTON STATE: TX ZIP: 77024 BUSINESS PHONE: 650.739.3939 MAIL ADDRESS: STREET 1: 12645 MEMORIAL DR., SUITE F1 #305 CITY: HOUSTON STATE: TX ZIP: 77024 D 1 primary_doc.xml X0708 D LIVE 0001835022 Coya Therapeutics, Inc. 5850 SAN FELIPE ST. SUITE 500 HOUSTON TX TEXAS 77057 1 (800) 587 8170 DELAWARE None None Corporation true 2020 Howard Berman 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Executive Officer Director Dov Goldstein 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Director Anabella Villalobos 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Director Ann Lee 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Director Hideki Garren 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Director David Snyder 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Executive Officer Adrian Hepner 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Executive Officer Greg MacMichael 5850 San Felipe St. Suite 500 Houston TX TEXAS 77057 Executive Officer Biotechnology Decline to Disclose 06b false 2022-04-05 false true true true false 0 Wilmington Capital Securities, LLC 133839 None None 600 OLD COUNTRY ROAD SUITE 200 GARDEN CITY NY NEW YORK 11530 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MO MISSOURI NV NEVADA NH NEW HAMPSHIRE NC NORTH CAROLINA OH OHIO PA PENNSYLVANIA TN TENNESSEE TX TEXAS VA VIRGINIA WV WEST VIRGINIA true 20000000 10443970 9556030 false 45 1400000 true 0 true Assumes maximum commissions earned. Excludes value of warrants to purchase shares of common stock in an amount equal to 7% of the aggregate number of shares of equity securities ultimately issued upon conversion of the notes. 0 true Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3 false Coya Therapeutics, Inc. /s/ Howard Berman Howard Berman CEO 2022-05-20